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Androgen-Deprivation Therapy
Is More Than Palliation in
Oligometastatic Prostate Cancer
TO THE EDITOR: Ost et al1 recently reported the results of a
randomized phase II study, which assessed the benefit of metastasis-
directed therapy (MDT) compared with surveillance for oligo-
recurrent prostate cancer (PCa). Sixty-two patients with PCa with
a prostate-specific antigen (PSA) relapse after local treatment with
curative intent and up to three extracranial metastases were ran-
domly assigned to either surveillance or MDT. The primary end
point was androgen-deprivation therapy (ADT) –free survival, de-
fined as the time between random assignment and the start of pal-
liative ADTor death. Mean PSA values at inclusion were 6.9 ng/mL
(range, 0.3 to 31.0 ng/mL) and 9 ng/mL (range, 0.7 to 44.5 ng/mL)
in the surveillance and MDT groups, respectively. Twenty-one
patients (33.9%) had regional node-limited disease, whereas 41
(66.1%) showed metastatic disease. Patients treated with MDTex-
perienced a longer ADT-free survival compared with those who
underwent surveillance alone (hazard ratio, 0.60; 80% CI, 0.40 to
0.90; log-rank P 5 .11); it seemed that the magnitude of benefit
with MDT was greater for those patients with a shorter PSA
doubling time. Safety of MDTwas excellent, and quality of life was
similar between arms. On the basis of these data, the authors con-
cluded that MDTwas a promising approach for oligorecurrent PCa
and should be explored in larger phase III studies.
Some limitations of this trial should be underlined. First, these
results are merely explorative, because the prespecified a and b
cutoff of 0.20 was not chosen to validate the superiority of a clinical
intervention but rather to determine which arm was justified to be
tested in a subsequent phase III trial; MDT improved ADT-free
survival compared with surveillance without statistical significance
using the standard a 5 0.05 cutoff (hazard ratio, 0.60; 80% CI,
0.31 to 1.13; log-rank P 5 .11). Second, it is easy to win without
a competitor. ADT is actually the gold standard for patients with
oligometastatic PCa, whereas surveillance or delayed ADT (control
arm) is only recommended in asymptomatic patients with a strong
wish to avoid treatment-related adverse effects.2 Immediate ADT
should be offered as first choice of treatment to all men who
experience relapse after radical treatment with curative intent,
consistent with the results from the phase III TOAD (Timing of
Androgen Deprivation) trial, which demonstrated a significant
improvement in overall survival with immediate ADT compared
with delayed intervention.3
Moreover, the results from STAMPEDE (Systemic Therapy in
Advancing or Metastatic Prostate Cancer: Evaluation of Drug
Efficacy) studies suggest that ADT in combination with docetaxel
or abiraterone may be used for selected cases of castration-naı̈ve
oligometastatic PCa.4,5 Initial aggressive systemic approaches in
oligorecurrent PCa may eradicate pre-existing subpopulations of
resistant tumor clones, thus improving survival and preventing
subsequent treatment-induced lineage crisis, which is character-
istic of advanced and highly pretreated PCa.6,7
Instead of surveillance, ADT or other systemic approaches
should represent the control arm of such a study. ADT-free survival
seems to be an inadequate end point for actual evidence, and cli-
nicians should not be encouraged to replace immediate ADTwith
MDT in patients with oligometastatic PCa.MDTmay be a promising
approach from a multimodal perspective, and additional trials
should probably investigate, in a larger sample size, the survival
benefit of MDT in combination with other systemic treatments,
which currently represent the standard of care.
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